Cipemastat
![]() | |
Names | |
---|---|
Preferred IUPAC name (2R,3R)-3-(Cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
IUPHAR/BPS |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C22H36N4O5 |
Molar mass | 436.553 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). ![]() ![]() ![]() Infobox references |
Chemical compound
Cipemastat (rINN, also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent.[1] It is being developed by Roche.
References
- ^ Hemmings F, Farhan M, Rowland J, Banken L, Jain R (2001). "Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis". Rheumatology (Oxford). 40 (5): 537–43. doi:10.1093/rheumatology/40.5.537. PMID 11371662.
- v
- t
- e